Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Equity (2022 - 2025)

Taysha Gene Therapies' Return on Equity history spans 4 years, with the latest figure at 0.4% for Q3 2025.

  • For Q3 2025, Return on Equity rose 42.0% year-over-year to 0.4%; the TTM value through Sep 2025 reached 0.4%, up 42.0%, while the annual FY2024 figure was 1.16%, 79.0% up from the prior year.
  • Return on Equity for Q3 2025 was 0.4% at Taysha Gene Therapies, up from 0.57% in the prior quarter.
  • Across five years, Return on Equity topped out at 19.13% in Q1 2023 and bottomed at 28.6% in Q4 2022.
  • The 4-year median for Return on Equity is 0.87% (2024), against an average of 1.17%.
  • The largest annual shift saw Return on Equity soared 2288bps in 2023 before it plummeted -2036bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 28.6% in 2022, then surged by 80bps to 5.72% in 2023, then skyrocketed by 82bps to 1.06% in 2024, then soared by 62bps to 0.4% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Return on Equity are 0.4% (Q3 2025), 0.57% (Q2 2025), and 1.3% (Q1 2025).